JavaScript is disabled
Our website requires JavaScript to function properly. For a better experience, please enable JavaScript in your browser settings before proceeding.
sb 243 c
SB-649868 is a dual orexin receptor antagonist that was being developed by GlaxoSmithKline as a treatment for insomnia.
A phase I clinical trial evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects. In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency. The subsequent phase II study added a 60 mg dose and observed dose-dependent sleep promotion.
The compound no longer appears to be under active development, with the last study posted to ClinicalTrials.gov completed in 2010.
View More On Wikipedia.org
A phase I clinical trial evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects. In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency. The subsequent phase II study added a 60 mg dose and observed dose-dependent sleep promotion.
The compound no longer appears to be under active development, with the last study posted to ClinicalTrials.gov completed in 2010.
View More On Wikipedia.org
-
A
Oregon HB3075 - Repeals Ballot Measure 114, jacks up fees, litigation only in Marion County
HB3075 I didn't see a dedicated thread, and I think this bill should have it's own space.
